Study on Carboplatin, Paclitaxel, and Gemcitabine for Ovarian Cancer
Author Information
Author(s): Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, A'Hern R, Gibbens I, Jenkins A, Shah R, Cole C, Pizzada O, Kaye S
Primary Institution: Institute of Cancer Research and Royal Marsden Hospital
Hypothesis
Is a sequential regimen of carboplatin followed by paclitaxel and gemcitabine feasible and effective for treating ovarian cancer?
Conclusion
The sequential treatment with carboplatin, paclitaxel, and gemcitabine is feasible and shows promising efficacy in treating advanced ovarian cancer.
Supporting Evidence
- 72% of patients completed all eight cycles of treatment.
- The overall response rate was 84% after the full treatment.
- Median progression-free survival was 19.5 months.
Takeaway
Doctors tested a new way to give chemotherapy to women with ovarian cancer, and it worked well for many of them.
Methodology
The study involved 53 women with advanced ovarian cancer receiving a sequential regimen of carboplatin followed by paclitaxel and gemcitabine.
Potential Biases
There may be risks of bias due to the non-randomized nature of the study.
Limitations
The study was limited by the small sample size and the potential for bias in patient selection.
Participant Demographics
The majority of participants were women aged 29 to 77, with advanced stage ovarian cancer.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 13.4–25.6 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website